Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Travere Therapeutics

02/06/2026 13:05

June 2 (Reuters) - Travere Therapeutics TVTX.O said on Tuesday it has signed a licensing pact with privately held biotech Everest Medicines to develop and commercialize an experimental kidney disease drug in a deal worth up to $1.14 billion.

Here are some details:
Under the agreement, Travere will receive exclusive rights to develop and sell the drug civorebrutinib outside China and parts of East and Southeast Asia.
Everest will receive $112.5 million upfront and up to about $1.03 billion if certain development, regulatory and sales milestones are met.
It will also get royalties on future sales.
Civorebrutinib, also known as EVER001, is an oral treatment being studied for rare kidney diseases driven by the immune system.
Travere markets two FDA-approved therapies for kidney-related conditions: Filspari for IgA nephropathy and focal segmental glomerulosclerosis, and Thiola for cystinuria.
The company said it plans to evaluate the drug in various rare kidney diseases, including primary membranous nephropathy, FSGS and minimal change disease.
Civorebrutinib is a BTK inhibitor that blocks B-cell signaling to reduce the production of harmful antibodies that accumulate in the kidneys, causing inflammation and damage.
Travere said the drug has generally been well tolerated so far.

 (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore)
 ((Padmanabhan.Ananthan@thomsonreuters.com;))